SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018Clinical case presentation- David Thomas, MD, PhDView Slideset
DBDavid BurgerPharmD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018The use of DAA’s in pregnancy in HCV infected mothers- David Burger, PharmD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018Viral Dynamics and the Search for an HIV Cure - Stephen Becker, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018Clinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far- Richard Koup, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018FDA perspective on parallel review (Not available)- Rochelle Fink, MD, JDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver- Andrea DennisView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Feasibility of Using Deep-learning-based Techniques for Liver Couinaud Segmentation and Proton Density Fat Fraction (PDFF) Estimation- Hashem AlmahmoudView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Neoepitope fragments of extracellular matrix as markers of fibrosis in chronic liver disease: Insights into clinical and preclinical utilization for unfolding disease pathogenesis - Diana Leeming, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana LeemingView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBSView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhDView Slideset
